Synthetic Biology Market by Product (Consumables & Reagents, Instruments, Services), Technology (Bioinformatics Tools, Cell Engineering, Gene Synthesis), Application, End User - Global Forecast 2025-2032
Description
The Synthetic Biology Market was valued at USD 13.67 billion in 2024 and is projected to grow to USD 15.80 billion in 2025, with a CAGR of 17.04%, reaching USD 48.18 billion by 2032.
A concise orientation to how converging technologies, commercial models, and regulatory trends are redefining strategic priorities across synthetic biology stakeholders
Synthetic biology has moved beyond a conceptual field to a strategic domain that is reshaping industries from healthcare to agriculture and specialty chemicals. Recent advances in platform automation, computational design, and molecular tools have lowered the barrier to engineering biology at scale, enabling a new generation of products and services. Investors, corporate strategists, and public sector stakeholders are increasingly treating synthetic biology as a systems-level opportunity where modular technologies converge to create differentiated value propositions.
This report provides a concise orientation to that evolution, emphasizing the interactions among product categories, enabling technologies, end-user needs, and regional dynamics. Rather than relying on single-issue narratives, the introduction situates synthetic biology within the broader innovation ecosystem where data analytics, laboratory automation, and novel business models interact. By establishing this context up-front, readers can better interpret the downstream analysis on regulatory shifts, tariff impacts, segmentation nuances, and actionable recommendations for market entry and scale-up strategies.
How convergent advances in computational design, molecular automation, and business model innovation are reshaping synthetic biology ecosystems and strategic playbooks
The landscape of synthetic biology is undergoing transformative shifts driven by simultaneous advances in computational design, molecular automation, and manufacturing scale-up. Bioinformatics tools have evolved from standalone analytics into integrated platforms that automate design-to-build cycles, enabling teams to iterate on genetic constructs with unprecedented speed. At the same time, cost declines in DNA synthesis and the maturation of genome editing modalities have democratized access to core capabilities, allowing smaller companies and academic groups to pursue applications that were previously the domain of large institutions.
Business models are also evolving as services and software providers diversify revenue streams to include subscription analytics, design-as-a-service, and performance-based contracts. This commercial sophistication interacts with regulatory and public acceptance dynamics, prompting many organizations to invest in transparent governance frameworks and traceability mechanisms. Supply chains are optimizing for resilience; firms increasingly prioritize dual-sourcing strategies, regional manufacturing nodes, and digital inventory controls to manage variability. Taken together, these shifts are creating a more modular, interoperable ecosystem in which partnerships, platform licensing, and vertical integration coexist as viable routes to scale.
The cumulative effects of recent United States tariff measures on synthetic biology inputs and supply chains, prompting sourcing diversification and regional manufacturing responses
In 2025, cumulative tariff actions and trade policy shifts introduced by the United States began to exert measurable pressure on the cost structures and sourcing strategies of organizations operating across the synthetic biology value chain. Input-sensitive categories such as specialty reagents, high-precision instruments, and custom DNA products experienced direct cost impacts, which in turn influenced procurement decisions and internal budgeting for research and development. Firms responded by accelerating supplier diversification and, in many cases, prioritizing regional suppliers to mitigate exposure to cross-border duties and logistics delays.
Beyond immediate cost increases, tariff-driven dynamics also affected longer-term strategic calculus. Some companies moved to localized manufacturing or co-manufacturing arrangements to shield critical production lines from policy volatility. Others adjusted product roadmaps to emphasize service-led offerings and digital tools that are less tariff-sensitive. Importantly, regulatory compliance and customs classification became operational priorities; businesses invested in enhanced customs expertise and product reclassification strategies to reduce duty liabilities. The net effect has been a rebalancing of the global supply chain, with greater emphasis on resilience and regionalization, while also exposing opportunities for domestic suppliers and contract manufacturers to capture incremental demand.
Deep segmentation analysis revealing where product categories, enabling technologies, application domains, and end-user profiles concentrate demand and strategic differentiation
Segmentation-driven insights reveal differential dynamics across product, technology, application, and end-user groupings that inform where value and friction are most pronounced. By product, consumables and reagents-including enzymes, proteins, kits, assays, and media-remain foundational to laboratory throughput and are subject to steady demand from both academic and commercial users. Instruments such as bioinformatics workstations, PCR machines, sequencers, and synthesizers represent high-capital investments that shape laboratory capabilities and catalyze adjacent services and software uptake. Services and software act as force multipliers, enabling higher utilization of physical assets while unlocking recurring revenue models.
When viewed through a technology lens, bioinformatics tools that span data management, design automation, and sequence analysis are central to shortening design cycles, while cell engineering efforts focused on cell line development and synthetic cell design are unlocking bespoke production platforms. Gene synthesis capabilities, including DNA printing, gene assembly, and oligonucleotide synthesis, are critical enablers for rapid prototyping. Genome editing modalities such as CRISPR and alternative nuclease systems drive precision interventions, and synthetic genomics approaches like minimal cell and xenobiology blur the lines between engineered organisms and programmatic biological systems.
Applications create clear pockets of opportunity and regulatory sensitivity. In agriculture, genetically modified crops and synthetic fertilizers promise productivity gains but are subject to approval cycles and public acceptance. Environmental use cases-bioremediation, carbon capture, and waste treatment-are increasingly attracting cross-sector partnerships that combine public funding with private deployment. Industrial applications such as biocatalysts, biofuels, bioplastics, and specialty chemicals highlight pathways to decarbonization and circularity, whereas life sciences applications in drug discovery, gene therapy, personalized medicine, and vaccine development continue to command premium investment because of clinical and regulatory value capture.
End-user segmentation underscores differing procurement, adoption, and risk preferences across academic and research institutes, agriculture and food companies, contract research organizations, and pharmaceutical and biotechnology companies. Academic groups often prioritize open platforms and publication-driven timelines, agriculture and food firms focus on field-scale validation and regulatory alignment, contract research organizations emphasize throughput and standardization, and pharmaceutical and biotech firms concentrate on translational robustness and IP protection. This multi-dimensional segmentation framework guides go-to-market strategies, partnership design, and product development priorities.
Comparative regional dynamics and strategic implications across the Americas, Europe–Middle East–Africa, and Asia-Pacific that determine commercialization pathways and policy interactions
Regional dynamics play a pivotal role in shaping research capabilities, investment flows, and commercialization pathways across the synthetic biology ecosystem. In the Americas, robust private capital markets, deep translational pipelines, and a concentration of industrial biomanufacturing capacity contribute to rapid commercialization of platform technologies. Policymakers and regional regulators are increasingly focused on harmonizing safety standards and promoting domestic resilience, which encourages companies to consider local production and strategic partnerships.
Europe, the Middle East, and Africa present a more heterogeneous picture where regulatory frameworks and public sentiment are major determinants of technology adoption. European markets often demand rigorous environmental and safety assessments, but they also provide strong public funding mechanisms for sustainability-focused applications such as bioremediation and bio-based materials. In several Middle Eastern jurisdictions, strategic investments target industrial-scale biomanufacturing as part of economic diversification plans, while parts of Africa emphasize capacity building, public health applications, and agriculture-focused innovations.
The Asia-Pacific region is characterized by rapid adoption, aggressive capacity expansion, and policy initiatives that favor scale-up of local manufacturing. Several countries are investing heavily in domestic capabilities across synthesis, sequencing, and downstream bioprocessing. Cross-border partnerships and contract manufacturing arrangements are common, and regulatory modernization efforts aim to streamline approval pathways for novel therapeutics and industrial applications. Taken together, these regional contrasts necessitate tailored market entry strategies and partnership models that reflect local regulatory, capital, and infrastructure realities.
How incumbents and startups are deploying platform integration, vertical strategies, and partnership-driven scaling to shape competitive advantage and commercialization success
Market incumbents and emergent challengers are shaping competitive dynamics through distinct strategies: platform consolidation, vertical integration, and nimble niche specialization. Leading organizations invest heavily in R&D infrastructure and proprietary platforms that integrate hardware, reagents, and software to create sticky customer relationships. Others pursue vertical integration to capture margins across design, build, and manufacturing stages, leveraging proprietary workflows to differentiate on speed and reproducibility.
At the same time, a vibrant cohort of startups is pursuing modular, interoperable solutions that lower adoption friction for end-users. These companies often partner with contract research organizations and academic institutions to validate use cases before scaling. Strategic partnerships between instrument manufacturers and software providers are also becoming more common, enabling bundled offerings that simplify procurement for enterprise customers. Intellectual property strategy, data governance, and regulatory engagement emerge as non-negotiable elements of competitive advantage, with successful firms demonstrating both technical differentiation and disciplined commercialization playbooks.
Actionable strategic steps for leaders to transform platform capabilities, secure resilient supply chains, and accelerate regulated commercialization across synthetic biology applications
Industry leaders should take deliberate, actionable steps to translate technological promise into durable commercial outcomes. First, organize around modular product architectures that allow rapid integration of bioinformatics, automation, and consumables; this reduces customer friction and accelerates adoption. Second, prioritize supply chain resilience by diversifying suppliers, qualifying regional partners, and investing in traceability systems that mitigate tariff and logistics risks. Third, develop regulatory and ethics engagement strategies that proactively shape policy discourse and de-risk approval pathways for sensitive applications.
Leaders should also consider hybrid business models that combine product sales with recurring services and data subscriptions to stabilize revenue and deepen customer relationships. Investing in strategic partnerships with academic centers and contract research organizations can shorten validation cycles and broaden market access. Finally, strengthen talent pipelines by combining life science expertise with software engineering and regulatory specialists; cross-functional teams are indispensable for translating modular technologies into industrialized solutions. These measures, taken together, will position organizations to capture the next wave of practical, scalable applications in synthetic biology.
A rigorous mixed-methods research approach combining expert interviews, case studies, and systematic secondary analysis to produce transparent and actionable synthetic biology insights
This research synthesized qualitative and quantitative approaches to produce an evidence-based perspective on synthetic biology market dynamics. Primary research included structured interviews with senior executives, technology leaders, and policy experts, complemented by detailed case studies of representative commercialization pathways. Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, patent filings, and public company disclosures to triangulate technology readiness and commercial traction.
The analysis emphasized reproducibility and transparency: methodologies for segment classification and regional mapping were explicitly codified, and assumptions about technological capability and regulatory timelines were vetted with subject-matter experts. Limitations are acknowledged, particularly where emerging technologies outpace formal regulatory guidance or where company-reported metrics require contextual interpretation. Where appropriate, sensitivity analyses were used to explore alternative strategic outcomes, enabling readers to understand the range of plausible scenarios and to adapt recommendations to their specific operational contexts.
Synthesis of strategic priorities for converting technological momentum into practical, responsible, and regionally tailored commercialization outcomes across synthetic biology
In conclusion, synthetic biology is at a pivotal juncture where technology maturation, commercial innovation, and policy evolution intersect to create new opportunities and operational challenges. The most successful organizations will be those that pair technical excellence with disciplined commercial strategies: modular product design, resilient supply chain architectures, and proactive regulatory engagement. Regional differences in capital availability, regulatory posture, and infrastructure require tailored approaches to market entry and scaling.
As the field moves from demonstration projects to industrial-scale deployments, leaders should focus on building interoperable ecosystems that incentivize openness while protecting core IP and data assets. Strategic partnerships, investment in talent that bridges biology and computation, and flexible business models will determine which organizations convert early promise into durable impact. By aligning these elements, stakeholders can accelerate responsible innovation that delivers measurable benefits across healthcare, agriculture, environment, and industrial applications.
Please Note: PDF & Excel + Online Access - 1 Year
A concise orientation to how converging technologies, commercial models, and regulatory trends are redefining strategic priorities across synthetic biology stakeholders
Synthetic biology has moved beyond a conceptual field to a strategic domain that is reshaping industries from healthcare to agriculture and specialty chemicals. Recent advances in platform automation, computational design, and molecular tools have lowered the barrier to engineering biology at scale, enabling a new generation of products and services. Investors, corporate strategists, and public sector stakeholders are increasingly treating synthetic biology as a systems-level opportunity where modular technologies converge to create differentiated value propositions.
This report provides a concise orientation to that evolution, emphasizing the interactions among product categories, enabling technologies, end-user needs, and regional dynamics. Rather than relying on single-issue narratives, the introduction situates synthetic biology within the broader innovation ecosystem where data analytics, laboratory automation, and novel business models interact. By establishing this context up-front, readers can better interpret the downstream analysis on regulatory shifts, tariff impacts, segmentation nuances, and actionable recommendations for market entry and scale-up strategies.
How convergent advances in computational design, molecular automation, and business model innovation are reshaping synthetic biology ecosystems and strategic playbooks
The landscape of synthetic biology is undergoing transformative shifts driven by simultaneous advances in computational design, molecular automation, and manufacturing scale-up. Bioinformatics tools have evolved from standalone analytics into integrated platforms that automate design-to-build cycles, enabling teams to iterate on genetic constructs with unprecedented speed. At the same time, cost declines in DNA synthesis and the maturation of genome editing modalities have democratized access to core capabilities, allowing smaller companies and academic groups to pursue applications that were previously the domain of large institutions.
Business models are also evolving as services and software providers diversify revenue streams to include subscription analytics, design-as-a-service, and performance-based contracts. This commercial sophistication interacts with regulatory and public acceptance dynamics, prompting many organizations to invest in transparent governance frameworks and traceability mechanisms. Supply chains are optimizing for resilience; firms increasingly prioritize dual-sourcing strategies, regional manufacturing nodes, and digital inventory controls to manage variability. Taken together, these shifts are creating a more modular, interoperable ecosystem in which partnerships, platform licensing, and vertical integration coexist as viable routes to scale.
The cumulative effects of recent United States tariff measures on synthetic biology inputs and supply chains, prompting sourcing diversification and regional manufacturing responses
In 2025, cumulative tariff actions and trade policy shifts introduced by the United States began to exert measurable pressure on the cost structures and sourcing strategies of organizations operating across the synthetic biology value chain. Input-sensitive categories such as specialty reagents, high-precision instruments, and custom DNA products experienced direct cost impacts, which in turn influenced procurement decisions and internal budgeting for research and development. Firms responded by accelerating supplier diversification and, in many cases, prioritizing regional suppliers to mitigate exposure to cross-border duties and logistics delays.
Beyond immediate cost increases, tariff-driven dynamics also affected longer-term strategic calculus. Some companies moved to localized manufacturing or co-manufacturing arrangements to shield critical production lines from policy volatility. Others adjusted product roadmaps to emphasize service-led offerings and digital tools that are less tariff-sensitive. Importantly, regulatory compliance and customs classification became operational priorities; businesses invested in enhanced customs expertise and product reclassification strategies to reduce duty liabilities. The net effect has been a rebalancing of the global supply chain, with greater emphasis on resilience and regionalization, while also exposing opportunities for domestic suppliers and contract manufacturers to capture incremental demand.
Deep segmentation analysis revealing where product categories, enabling technologies, application domains, and end-user profiles concentrate demand and strategic differentiation
Segmentation-driven insights reveal differential dynamics across product, technology, application, and end-user groupings that inform where value and friction are most pronounced. By product, consumables and reagents-including enzymes, proteins, kits, assays, and media-remain foundational to laboratory throughput and are subject to steady demand from both academic and commercial users. Instruments such as bioinformatics workstations, PCR machines, sequencers, and synthesizers represent high-capital investments that shape laboratory capabilities and catalyze adjacent services and software uptake. Services and software act as force multipliers, enabling higher utilization of physical assets while unlocking recurring revenue models.
When viewed through a technology lens, bioinformatics tools that span data management, design automation, and sequence analysis are central to shortening design cycles, while cell engineering efforts focused on cell line development and synthetic cell design are unlocking bespoke production platforms. Gene synthesis capabilities, including DNA printing, gene assembly, and oligonucleotide synthesis, are critical enablers for rapid prototyping. Genome editing modalities such as CRISPR and alternative nuclease systems drive precision interventions, and synthetic genomics approaches like minimal cell and xenobiology blur the lines between engineered organisms and programmatic biological systems.
Applications create clear pockets of opportunity and regulatory sensitivity. In agriculture, genetically modified crops and synthetic fertilizers promise productivity gains but are subject to approval cycles and public acceptance. Environmental use cases-bioremediation, carbon capture, and waste treatment-are increasingly attracting cross-sector partnerships that combine public funding with private deployment. Industrial applications such as biocatalysts, biofuels, bioplastics, and specialty chemicals highlight pathways to decarbonization and circularity, whereas life sciences applications in drug discovery, gene therapy, personalized medicine, and vaccine development continue to command premium investment because of clinical and regulatory value capture.
End-user segmentation underscores differing procurement, adoption, and risk preferences across academic and research institutes, agriculture and food companies, contract research organizations, and pharmaceutical and biotechnology companies. Academic groups often prioritize open platforms and publication-driven timelines, agriculture and food firms focus on field-scale validation and regulatory alignment, contract research organizations emphasize throughput and standardization, and pharmaceutical and biotech firms concentrate on translational robustness and IP protection. This multi-dimensional segmentation framework guides go-to-market strategies, partnership design, and product development priorities.
Comparative regional dynamics and strategic implications across the Americas, Europe–Middle East–Africa, and Asia-Pacific that determine commercialization pathways and policy interactions
Regional dynamics play a pivotal role in shaping research capabilities, investment flows, and commercialization pathways across the synthetic biology ecosystem. In the Americas, robust private capital markets, deep translational pipelines, and a concentration of industrial biomanufacturing capacity contribute to rapid commercialization of platform technologies. Policymakers and regional regulators are increasingly focused on harmonizing safety standards and promoting domestic resilience, which encourages companies to consider local production and strategic partnerships.
Europe, the Middle East, and Africa present a more heterogeneous picture where regulatory frameworks and public sentiment are major determinants of technology adoption. European markets often demand rigorous environmental and safety assessments, but they also provide strong public funding mechanisms for sustainability-focused applications such as bioremediation and bio-based materials. In several Middle Eastern jurisdictions, strategic investments target industrial-scale biomanufacturing as part of economic diversification plans, while parts of Africa emphasize capacity building, public health applications, and agriculture-focused innovations.
The Asia-Pacific region is characterized by rapid adoption, aggressive capacity expansion, and policy initiatives that favor scale-up of local manufacturing. Several countries are investing heavily in domestic capabilities across synthesis, sequencing, and downstream bioprocessing. Cross-border partnerships and contract manufacturing arrangements are common, and regulatory modernization efforts aim to streamline approval pathways for novel therapeutics and industrial applications. Taken together, these regional contrasts necessitate tailored market entry strategies and partnership models that reflect local regulatory, capital, and infrastructure realities.
How incumbents and startups are deploying platform integration, vertical strategies, and partnership-driven scaling to shape competitive advantage and commercialization success
Market incumbents and emergent challengers are shaping competitive dynamics through distinct strategies: platform consolidation, vertical integration, and nimble niche specialization. Leading organizations invest heavily in R&D infrastructure and proprietary platforms that integrate hardware, reagents, and software to create sticky customer relationships. Others pursue vertical integration to capture margins across design, build, and manufacturing stages, leveraging proprietary workflows to differentiate on speed and reproducibility.
At the same time, a vibrant cohort of startups is pursuing modular, interoperable solutions that lower adoption friction for end-users. These companies often partner with contract research organizations and academic institutions to validate use cases before scaling. Strategic partnerships between instrument manufacturers and software providers are also becoming more common, enabling bundled offerings that simplify procurement for enterprise customers. Intellectual property strategy, data governance, and regulatory engagement emerge as non-negotiable elements of competitive advantage, with successful firms demonstrating both technical differentiation and disciplined commercialization playbooks.
Actionable strategic steps for leaders to transform platform capabilities, secure resilient supply chains, and accelerate regulated commercialization across synthetic biology applications
Industry leaders should take deliberate, actionable steps to translate technological promise into durable commercial outcomes. First, organize around modular product architectures that allow rapid integration of bioinformatics, automation, and consumables; this reduces customer friction and accelerates adoption. Second, prioritize supply chain resilience by diversifying suppliers, qualifying regional partners, and investing in traceability systems that mitigate tariff and logistics risks. Third, develop regulatory and ethics engagement strategies that proactively shape policy discourse and de-risk approval pathways for sensitive applications.
Leaders should also consider hybrid business models that combine product sales with recurring services and data subscriptions to stabilize revenue and deepen customer relationships. Investing in strategic partnerships with academic centers and contract research organizations can shorten validation cycles and broaden market access. Finally, strengthen talent pipelines by combining life science expertise with software engineering and regulatory specialists; cross-functional teams are indispensable for translating modular technologies into industrialized solutions. These measures, taken together, will position organizations to capture the next wave of practical, scalable applications in synthetic biology.
A rigorous mixed-methods research approach combining expert interviews, case studies, and systematic secondary analysis to produce transparent and actionable synthetic biology insights
This research synthesized qualitative and quantitative approaches to produce an evidence-based perspective on synthetic biology market dynamics. Primary research included structured interviews with senior executives, technology leaders, and policy experts, complemented by detailed case studies of representative commercialization pathways. Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, patent filings, and public company disclosures to triangulate technology readiness and commercial traction.
The analysis emphasized reproducibility and transparency: methodologies for segment classification and regional mapping were explicitly codified, and assumptions about technological capability and regulatory timelines were vetted with subject-matter experts. Limitations are acknowledged, particularly where emerging technologies outpace formal regulatory guidance or where company-reported metrics require contextual interpretation. Where appropriate, sensitivity analyses were used to explore alternative strategic outcomes, enabling readers to understand the range of plausible scenarios and to adapt recommendations to their specific operational contexts.
Synthesis of strategic priorities for converting technological momentum into practical, responsible, and regionally tailored commercialization outcomes across synthetic biology
In conclusion, synthetic biology is at a pivotal juncture where technology maturation, commercial innovation, and policy evolution intersect to create new opportunities and operational challenges. The most successful organizations will be those that pair technical excellence with disciplined commercial strategies: modular product design, resilient supply chain architectures, and proactive regulatory engagement. Regional differences in capital availability, regulatory posture, and infrastructure require tailored approaches to market entry and scaling.
As the field moves from demonstration projects to industrial-scale deployments, leaders should focus on building interoperable ecosystems that incentivize openness while protecting core IP and data assets. Strategic partnerships, investment in talent that bridges biology and computation, and flexible business models will determine which organizations convert early promise into durable impact. By aligning these elements, stakeholders can accelerate responsible innovation that delivers measurable benefits across healthcare, agriculture, environment, and industrial applications.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Development of programmable cell therapies leveraging CRISPR-based gene circuits to target solid tumors
- 5.2. Scaling up microbial fermentation for sustainable production of high-value bio-based chemicals at industrial scale
- 5.3. Integration of AI-driven design and machine learning for accelerated biosynthetic pathway optimization in microbes
- 5.4. Adoption of cell-free synthetic biology platforms for rapid prototyping and on-demand biomanufacturing of therapeutics
- 5.5. Advancements in modular protein scaffolding for precise enzyme colocalization in metabolic engineering
- 5.6. Regulatory landscape evolution for synthetic biology products enabling faster approvals across major markets
- 5.7. Investment surge in biocontainment strategies to address safety concerns for environmental release of engineered organisms
- 5.8. Commercialization of synthetic biology derived cultured meat products with improved texture and cost competitiveness
- 5.9. Development of biofoundries integrating robotics and high throughput analytics for automated strain engineering workflows
- 5.10. Emergence of synthetic minimal cells as versatile chassis for custom biosensing and environmental remediation
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Synthetic Biology Market, by Product
- 8.1. Consumables & Reagents
- 8.1.1. Enzymes & Proteins
- 8.1.2. Kits & Assays
- 8.1.3. Media & Supplements
- 8.2. Instruments
- 8.2.1. Bioinformatics Workstations
- 8.2.2. PCR Machines
- 8.2.3. Sequencers
- 8.2.4. Synthesizers
- 8.3. Services
- 8.4. Software
- 9. Synthetic Biology Market, by Technology
- 9.1. Bioinformatics Tools
- 9.1.1. Data Management
- 9.1.2. Design Automation
- 9.1.3. Sequence Analysis
- 9.2. Cell Engineering
- 9.2.1. Cell Line Development
- 9.2.2. Synthetic Cell Design
- 9.3. Gene Synthesis
- 9.3.1. DNA Printing
- 9.3.2. Gene Assembly
- 9.3.3. Oligonucleotide Synthesis
- 9.4. Genome Editing
- 9.4.1. CRISPR Cas
- 9.4.2. Meganucleases
- 9.5. Synthetic Genomics
- 9.5.1. Minimal Cell
- 9.5.2. Xenobiology
- 10. Synthetic Biology Market, by Application
- 10.1. Agriculture
- 10.1.1. Genetically Modified Crops
- 10.1.2. Synthetic Fertilizers
- 10.2. Environmental
- 10.2.1. Bioremediation
- 10.2.2. Carbon Capture
- 10.2.3. Waste Treatment
- 10.3. Industrial
- 10.3.1. Biocatalysts
- 10.3.2. Biofuels
- 10.3.3. Bioplastics & Biopolymers
- 10.3.4. Specialty Chemicals
- 10.4. Life Sciences
- 10.4.1. Drug Discovery
- 10.4.2. Gene Therapy
- 10.4.3. Personalized Medicine
- 10.4.4. Vaccine Development
- 11. Synthetic Biology Market, by End User
- 11.1. Academic & Research Institutes
- 11.2. Agriculture & Food Companies
- 11.3. Contract Research Organizations
- 11.4. Pharmaceutical & Biotechnology Companies
- 12. Synthetic Biology Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Synthetic Biology Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Synthetic Biology Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Agilent Technologies, Inc.
- 15.3.2. Amyris, Inc.
- 15.3.3. Arzeda
- 15.3.4. Batavia Biosciences B.V.
- 15.3.5. Beam Therapeutics
- 15.3.6. Beckman Coulter, Inc. by Danaher Corporation
- 15.3.7. BGI Genomics Co., Ltd.
- 15.3.8. Codexis, Inc.
- 15.3.9. Conagen, Inc.
- 15.3.10. Creative Enzymes
- 15.3.11. DNA TwoPointO Inc.
- 15.3.12. Editas Medicine, Inc.
- 15.3.13. Eurofins Scientific SE
- 15.3.14. GenScript Biotech Corporation
- 15.3.15. Ginkgo Bioworks, Inc.
- 15.3.16. Illumina, Inc.
- 15.3.17. Integrated DNA Technologies, Inc.
- 15.3.18. Merck KGaA
- 15.3.19. New England Biolabs GmbH
- 15.3.20. Novozymes A/S
- 15.3.21. Precigen, Inc.
- 15.3.22. QIAGEN N.V.
- 15.3.23. Sangamo Therapeutics
- 15.3.24. Scarab Genomics, LLC
- 15.3.25. Synlogic
- 15.3.26. Synthego Corporation
- 15.3.27. TeselaGen Service
- 15.3.28. Thermo Fisher Scientific Inc.
- 15.3.29. Twist Bioscience Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
